1-2 of 2
E. Wattel, MD
Close
Save search
Sort by
Journal Articles

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Free
Sylvain Thepot, Simone Boehrer, MD, Thomas Prebet, Odile Beyne-Rauzy, E. Wattel, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Francois Dreyfus, Stefan Wickenhauser, Mathilde Hunault-Berger, MD, PhD, Fatiha Chermat, Pierre Fenaux, MD, PhD, Lionel Ades, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1719.
https://doi.org/10.1182/blood.V120.21.1719.1719
Published: 2012
Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Free
Simone Boehrer, MD, Odile Beyne-Rauzy, MD, Thomas Prebet, M.D., Ph.D., Sophie Park, MD, PhD, Agnès Guerci, MD, Aspasia Stamatoulas, MD, MP Chaury, MD, Tony Jernival, Laurence Sanhes, MD, Gerard Tertian, MD, Stephane Cheze, MD, Eng-Mong Lim, Bachra Choufi, MD, Denis Caillot, MD, E. Wattel, MD, Jacques Delaunay, MD, Laurence Legros, MD, Fatiha Chermat, Françoise Isnard, MD, N. Cambier, MD, Borhane Slama, MD, Lydia Roy, MD, Gandhi Damaj, MD, Emmanuel Raffoux, MD, Francois Dreyfus, MD, Christian Récher, MD, Norbert Vey, MD, Sylvie Chevret, PhD, Pierre Fenaux, MD, PhD, Claude Gardin, MD
Journal: Blood
Blood (2010) 116 (21): 1880.
https://doi.org/10.1182/blood.V116.21.1880.1880
Published: 2010